Fig. 5

Survival plots for SCC patients, combining classical HLA and HLA-G expression in the primary tumor. 5 year disease-specific survival (DSS) (a) and disease-free survival (DFS) (b) curves for SCC patients in relation to HLA-A/HLA-G expression and total classical HLA/HLA-G expression in the primary tumor. Both patient groups with down-regulated HLA-A(-) or total classical HLA(-) in combination with HLA-G expression had the poorest survival (red line). Log Rank test P-value combining all groups, * Log Rank test P-value between classical HLA(-)/HLA-G(+) (red line) and classical HLA(-)/HLA-G(-) (yellow line)